BARDA awards $483m to scale production of Moderna’s COVID vaccine

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Aristeer)
(Image: Getty/Aristeer)

Related tags Coronavirus COVID-19 Moderna mRNA Vaccine

With recruitment for Phase I trials complete, Moderna receives funds to expand manufacturing capacity ready for late-stage trials.

After racing from discovery to first-in-human studies in just 63 days​, the US Biomedical Advanced Research and Development Authority (BARDA) has backed Moderna’s mRNA vaccine by agreeing to commit up to $483m (€446m) in funds. The investment could potentially push the vaccine through to Phase III trials and enable the scale up manufacture.

In a joint release, the two organizations suggested that Phase III studies could begin by this coming fall and that capacity of production will be expanded to ‘enable a potential pandemic response’ during this year.

In order for the company to move the vaccine so rapidly from early-stage to potentially delivering it to the public, Moderna will hire 150 additional team members in the US this year.

A number of these new employees will focus on manufacturing of the vaccine, with Moderna noting that they will work on managing the scale-up by enabling staff to rotate around performing three shifts per day, seven days per week.

Stéphane Bancel, Moderna’s CEO, explained what the aim for the funding is: “By investing now in our manufacturing process scale-up to enable large scale production for pandemic response, we believe that we would be able to supply millions of doses per month in 2020 and with further investments, tens of millions per month in 2021, if the vaccine candidate is successful in the clinic.”

The Phase I that began in March was confirmed as having completed enrollment, with 45 adults volunteering to the trial between the ages of 18 to 55 years old. In addition, six additional cohorts will be added with older adults in two different age groups, 56-70 years of age and 71 years and above.

Should safety of the mRNA vaccine be proven in this trial, a Phase II trial is expected in the second quarter and a Phase III trial subsequently following later this year.

Related news

Show more

Related products

Trends in Biopharmaceutical Raw Material Selection

Trends in Biopharmaceutical Raw Material Selection

Actylis – The Partner of Choice | 31-Jan-2023 | Business Advice

Join us as our in-house experts, along with Cecile Bellamy from Pfizer, discuss current and future trends in biopharmaceutical raw material selection.

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more